Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival

Shomik Sengupta, Michael L. Blute, Stephanie M. Bagniewski, Robert P. Myers, Eric J. Bergstralh, Bradley C. Leibovich, Horst Zincke

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Adjuvant hormonal therapy may be beneficial in patients who are treated with RRP and found to have adverse pathological findings. We assessed the natural history of detectable PSA in such patients with particular emphasis on the prognostic usefulness of PSADT. Materials and Methods: We identified 903 patients treated with RRP and adjuvant hormonal therapy (started less than 90 days postoperatively) for prostate cancer at our institution between 1990 and 1999. PSADT was calculated by log linear regression in men with 2 or more PSA measurements available at least 90 days apart. CSS and sRFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: At a median followup of 9.1 years PSA had become detectable in 369 of 771 patients (47.9%) who achieved an undetectable nadir. PSADT evaluable in 463 patients was less than 12 months in 68 (14.6%) and more than 10 years in 283 (61.1%). N stage and Gleason score were significantly associated with sRFS and CSS. PSADT was a significant predictor of sRFS and CSS in N+ and N0 cases with a cancer death HR of 0.55 (95% CI 0.43 to 0.71) and 0.50 (95% CI 0.31 to 0.79), respectively. The association between PSADT and survival persisted after multivariate adjustment for preoperative PSA, specimen Gleason score and seminal vesicle invasion. Conclusions: This study demonstrates that many patients have slow progression despite increasing PSA following RRP and adjuvant hormonal therapy. Nodal status, cancer grade and PSADT are predictive of sRFS and CSS, and may be a useful means of selecting patients for future adjuvant therapy trials.

Original languageEnglish (US)
Pages (from-to)1684-1690
Number of pages7
JournalJournal of Urology
Volume175
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Survival
Neoplasm Grading
Therapeutics
Seminal Vesicles
Natural History
Proportional Hazards Models
Linear Models
Neoplasms
Prostatic Neoplasms

Keywords

  • mortality
  • prostate
  • prostate-specific antigen
  • prostatectomy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Sengupta, S., Blute, M. L., Bagniewski, S. M., Myers, R. P., Bergstralh, E. J., Leibovich, B. C., & Zincke, H. (2006). Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival. Journal of Urology, 175(5), 1684-1690. https://doi.org/10.1016/S0022-5347(05)00978-X

Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy : Doubling Time Predicts Survival. / Sengupta, Shomik; Blute, Michael L.; Bagniewski, Stephanie M.; Myers, Robert P.; Bergstralh, Eric J.; Leibovich, Bradley C.; Zincke, Horst.

In: Journal of Urology, Vol. 175, No. 5, 05.2006, p. 1684-1690.

Research output: Contribution to journalArticle

Sengupta, S, Blute, ML, Bagniewski, SM, Myers, RP, Bergstralh, EJ, Leibovich, BC & Zincke, H 2006, 'Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival', Journal of Urology, vol. 175, no. 5, pp. 1684-1690. https://doi.org/10.1016/S0022-5347(05)00978-X
Sengupta, Shomik ; Blute, Michael L. ; Bagniewski, Stephanie M. ; Myers, Robert P. ; Bergstralh, Eric J. ; Leibovich, Bradley C. ; Zincke, Horst. / Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy : Doubling Time Predicts Survival. In: Journal of Urology. 2006 ; Vol. 175, No. 5. pp. 1684-1690.
@article{85036443b03344899dbf666003bd578a,
title = "Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival",
abstract = "Purpose: Adjuvant hormonal therapy may be beneficial in patients who are treated with RRP and found to have adverse pathological findings. We assessed the natural history of detectable PSA in such patients with particular emphasis on the prognostic usefulness of PSADT. Materials and Methods: We identified 903 patients treated with RRP and adjuvant hormonal therapy (started less than 90 days postoperatively) for prostate cancer at our institution between 1990 and 1999. PSADT was calculated by log linear regression in men with 2 or more PSA measurements available at least 90 days apart. CSS and sRFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: At a median followup of 9.1 years PSA had become detectable in 369 of 771 patients (47.9{\%}) who achieved an undetectable nadir. PSADT evaluable in 463 patients was less than 12 months in 68 (14.6{\%}) and more than 10 years in 283 (61.1{\%}). N stage and Gleason score were significantly associated with sRFS and CSS. PSADT was a significant predictor of sRFS and CSS in N+ and N0 cases with a cancer death HR of 0.55 (95{\%} CI 0.43 to 0.71) and 0.50 (95{\%} CI 0.31 to 0.79), respectively. The association between PSADT and survival persisted after multivariate adjustment for preoperative PSA, specimen Gleason score and seminal vesicle invasion. Conclusions: This study demonstrates that many patients have slow progression despite increasing PSA following RRP and adjuvant hormonal therapy. Nodal status, cancer grade and PSADT are predictive of sRFS and CSS, and may be a useful means of selecting patients for future adjuvant therapy trials.",
keywords = "mortality, prostate, prostate-specific antigen, prostatectomy, prostatic neoplasms",
author = "Shomik Sengupta and Blute, {Michael L.} and Bagniewski, {Stephanie M.} and Myers, {Robert P.} and Bergstralh, {Eric J.} and Leibovich, {Bradley C.} and Horst Zincke",
year = "2006",
month = "5",
doi = "10.1016/S0022-5347(05)00978-X",
language = "English (US)",
volume = "175",
pages = "1684--1690",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy

T2 - Doubling Time Predicts Survival

AU - Sengupta, Shomik

AU - Blute, Michael L.

AU - Bagniewski, Stephanie M.

AU - Myers, Robert P.

AU - Bergstralh, Eric J.

AU - Leibovich, Bradley C.

AU - Zincke, Horst

PY - 2006/5

Y1 - 2006/5

N2 - Purpose: Adjuvant hormonal therapy may be beneficial in patients who are treated with RRP and found to have adverse pathological findings. We assessed the natural history of detectable PSA in such patients with particular emphasis on the prognostic usefulness of PSADT. Materials and Methods: We identified 903 patients treated with RRP and adjuvant hormonal therapy (started less than 90 days postoperatively) for prostate cancer at our institution between 1990 and 1999. PSADT was calculated by log linear regression in men with 2 or more PSA measurements available at least 90 days apart. CSS and sRFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: At a median followup of 9.1 years PSA had become detectable in 369 of 771 patients (47.9%) who achieved an undetectable nadir. PSADT evaluable in 463 patients was less than 12 months in 68 (14.6%) and more than 10 years in 283 (61.1%). N stage and Gleason score were significantly associated with sRFS and CSS. PSADT was a significant predictor of sRFS and CSS in N+ and N0 cases with a cancer death HR of 0.55 (95% CI 0.43 to 0.71) and 0.50 (95% CI 0.31 to 0.79), respectively. The association between PSADT and survival persisted after multivariate adjustment for preoperative PSA, specimen Gleason score and seminal vesicle invasion. Conclusions: This study demonstrates that many patients have slow progression despite increasing PSA following RRP and adjuvant hormonal therapy. Nodal status, cancer grade and PSADT are predictive of sRFS and CSS, and may be a useful means of selecting patients for future adjuvant therapy trials.

AB - Purpose: Adjuvant hormonal therapy may be beneficial in patients who are treated with RRP and found to have adverse pathological findings. We assessed the natural history of detectable PSA in such patients with particular emphasis on the prognostic usefulness of PSADT. Materials and Methods: We identified 903 patients treated with RRP and adjuvant hormonal therapy (started less than 90 days postoperatively) for prostate cancer at our institution between 1990 and 1999. PSADT was calculated by log linear regression in men with 2 or more PSA measurements available at least 90 days apart. CSS and sRFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: At a median followup of 9.1 years PSA had become detectable in 369 of 771 patients (47.9%) who achieved an undetectable nadir. PSADT evaluable in 463 patients was less than 12 months in 68 (14.6%) and more than 10 years in 283 (61.1%). N stage and Gleason score were significantly associated with sRFS and CSS. PSADT was a significant predictor of sRFS and CSS in N+ and N0 cases with a cancer death HR of 0.55 (95% CI 0.43 to 0.71) and 0.50 (95% CI 0.31 to 0.79), respectively. The association between PSADT and survival persisted after multivariate adjustment for preoperative PSA, specimen Gleason score and seminal vesicle invasion. Conclusions: This study demonstrates that many patients have slow progression despite increasing PSA following RRP and adjuvant hormonal therapy. Nodal status, cancer grade and PSADT are predictive of sRFS and CSS, and may be a useful means of selecting patients for future adjuvant therapy trials.

KW - mortality

KW - prostate

KW - prostate-specific antigen

KW - prostatectomy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=33645964608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645964608&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)00978-X

DO - 10.1016/S0022-5347(05)00978-X

M3 - Article

C2 - 16600730

AN - SCOPUS:33645964608

VL - 175

SP - 1684

EP - 1690

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -